- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03969134
A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL
A Phase IIb Study to Assess the Safety, Efficacy and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-kala Azar Dermal Leishmaniasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a randomised, double blinded, placebo controlled trial designed to assess the therapeutic efficacy and safety of CHAd63-KH, a new candidate Leishmania vaccine, in patients with persistent PKDL. 100 participants will be randomly assigned (50 participants in each arm) to receive placebo or ChAd63-KH 7.5 x10(10)vp intramuscular injection into the deltoid region. Doses will be administered at a single time point. Volunteers aged between 12-50 years with persistent PKDL will be recruited at Professor El-Hassan's Centre for Tropical Medicine, Dooka, Gedarif State, Sudan, and will be followed up for 120 days after the dosing visit. The trial is planned to run for 24 months.
Secondary objectives are as follows:
- To compare the humoral and cellular immune responses generated by the candidate vaccine in patients with persistent PKDL.
- To observe any clinical changes in the cutaneous PKDL disease over a 120 day period following vaccination
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Gedarif
-
Doka, Gedarif, Sudan
- Institute of Tropical Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
The volunteer must be:
- Aged 12 to 50 years on the day of screening
- Females must be unmarried, single, or widowed
- Willing and able to give written informed consent
- For adolescents aged 12 to 17 years on the day of screening written informed consent from a parent must be obtained and assent from them.
All Participants
- Uncomplicated PKDL of > 6 month's duration
- Available for the duration of the study
- In otherwise good health as determined by medical history, physical examination, results of screening tests and the clinical judgment of a medically qualified Clinical Investigator
- Negative for malaria on blood smear
- Judged, in the opinion of a medically qualified Clinical Investigator, to be able and likely to comply with all study requirements as set out in the protocol
- Willing to undergo screening for HIV, Hepatitis B and Hepatitis C
- Leishmania PCR positive on the screening skin biopsy
- For females only, willing to undergo urinary pregnancy tests on the day of screening, on the day of vaccination (prior to vaccination) and 7 and 42 days after vaccination.
Exclusion Criteria:
The volunteer may not enter the study if any of the following apply:
- Has mucosal or conjunctival PKDL
- Has had treatment for PKDL within 21 days
- Receipt of a live attenuated vaccine within 60 days or other vaccine within 14 days of screening
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine or a history of severe or multiple allergies to drugs or pharmaceutical agents
- Any history of severe local or general reaction to vaccination as defined as
- Local: extensive, indurated redness and swelling involving most of the antero-lateral thigh or the major circumference of the arm, not resolving within 72 hours
- General: fever ≥ 39.5°C within 48 hours, anaphylaxis, bronchospasm, laryngeal oedema, collapse, convulsions or encephalopathy within 48 hours
- Females - pregnancy, less than 12 weeks postpartum, lactating or willingness/intention to become pregnant during the study and for 3 months following vaccination.
- Seropositive for hepatitis B surface antigen (HBsAg) or Hepatitis C (antibodies to HCV)
- Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months
- Tuberculosis, leprosy, or malnutrition (malnutrition in adults defined as a BMI <18.5, and in adolescents (12-17yrs) as a Z score cut-off value of <-2 SD).
- Any other significant disease, disorder or finding, which, in the opinion of a medically qualified Clinical Investigator, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study
- Unlikely to comply with the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vaccine arm
ChAd63 KH 7.5x1010 vp, single dose, by IM injection
|
The vaccine will be injected intramuscularly into the arm.
|
Placebo Comparator: Placebo
Normal Saline, single dose, by IM injection
|
The placebo will be injected intramuscularly into the arm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the number of participants with treatment-related adverse events as defined in the clinical trial protocol V1.0.
Time Frame: 24 months
|
To assess the number of participants with treatment-related adverse events as defined in the clinical trial protocol V1.0.
|
24 months
|
To assess the therapeutic efficacy of CHAd63-KH, a new candidate, in patients with PKDL by clinical judgement of PKDL lesion reduction.
Time Frame: 24 months
|
To assess the therapeutic efficacy of CHAd63-KH, a new candidate, in patients with PKDL by clinical judgement of PKDL lesion reduction.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune responses by presence of interferon gamma producing T cells
Time Frame: 24 months
|
To identify cellular immune responses generated by the candidate vaccine in patients with persistent PKDL using a gamma interferon ELISpot assay
|
24 months
|
Immune responses by presence of serum antibodies against Leishmania peptides
Time Frame: 24 months
|
To identify humoral immune responses generated by the candidate vaccine in patients with persistent PKDL using a gamma interferon ELISpot assay
|
24 months
|
Clinical changes in PKDL disease
Time Frame: 24 months
|
To observe any changes in the appearance of the cutaneous PKDL disease over a 120 day period following vaccination.
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LEISH2b
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leishmaniasis, Cutaneous
-
Medecins Sans Frontieres, NetherlandsUnknownOld World Cutaneous Leishmaniasis
-
Drugs for Neglected DiseasesWellcome Trust grant 212346/Z/18/Z - 21st Century Treatments for Sustainable...CompletedVisceral Leishmaniasis | Cutaneous LeishmaniasesUnited Kingdom
-
Hospital Universitário Professor Edgard SantosOswaldo Cruz Foundation; Conselho Nacional de Desenvolvimento Científico e...CompletedCutaneous Leishmaniasis, AmericanBrazil
-
Fundacion Nacional de DermatologiaHospital Dermatologico de Jorochito; Ministerio de Salud de Bolivia, Programa... and other collaboratorsCompletedCutaneous Leishmaniasis, AmericanBolivia
-
Centro Internacional de Entrenamiento e Investigaciones...University of TexasCompletedCutaneous Leishmaniasis (Diagnosis)Colombia
-
Knight Therapeutics (USA) IncCompletedCutaneous Leishmaniasis | Mucosal LeishmaniasisUnited States
-
Hospital Universitário Professor Edgard SantosInstituto Gonçalo Muniz FIOCRUZ BANot yet recruitingCutaneous Leishmaniasis, AmericanBrazil
-
Centro Internacional de Entrenamiento e Investigaciones...Universidad IcesiCompletedCutaneous Leishmaniasis, AmericanColombia
-
University of BrasiliaCompletedLocalized Cutaneous LeishmaniasisBrazil
-
U.S. Army Medical Research and Development CommandCompletedOld World Cutaneous LeishmaniasisTunisia
Clinical Trials on ChAd63-KH
-
University of YorkUniversity of KhartoumCompleted
-
University of YorkWellcome Trust; European and Developing Countries Clinical Trials Partnership... and other collaboratorsWithdrawnPost-kala-azar Dermal Leishmaniasis
-
University Health Network, TorontoSunnybrook Health Sciences Centre; The Ottawa Hospital; Scarborough General HospitalRecruiting
-
University of OxfordCompleted
-
University of OxfordEuropean CommissionCompletedMalaria | Plasmodium FalciparumUnited Kingdom
-
U.S. Army Medical Research and Development CommandUnited States Agency for International Development (USAID); University of Oxford and other collaboratorsCompleted
-
University of OxfordCompletedPlasmodium Falciparum MalariaUnited Kingdom
-
University of OxfordCompleted
-
University of OxfordCompleted
-
University of OxfordCompleted